In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Hematology tests include various blood tests that help diagnose and monitor various conditions. GlobalData uses proprietary data and analytics to provide a comprehensive report on the hematology tests devices market, including market shares of different players within New Zealand. Buy the latest report here.
In 2022, GlobalData’s Market Model methodology determined that the leading player in the hematology tests market in New Zealand was Sysmex followed by Abbott Laboratories, Horiba, Danaher, F. Hoffmann-La Roche, EKF Diagnostics, Siemens and Thermo Fisher Scientific.
Hematology tests includes the sub-segments Complete Blood Count (CBC) Tests, Hemoglobin Laboratory Tests, Hemoglobin Point of Care (POC) Tests, Hematocrit Point of Care (POC) Tests, Hemoglobin & Hematocrit POC Tests, Erythrocytes Point of Care (POC) Tests, White Blood Count Point of Care (POC) Tests and Platelets Point of Care (POC) Tests.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the hematology tests devices market within New Zealand was expected to be over $4m in 2022.
For the latest complete market share analysis of hematology tests device market in New Zealand, buy the report here.